In the USA, before a patient can receive certain treatments or medications, a prior authorisation from their health insurance company is needed. A new USA-wide survey by the American Society for Radiation Oncology (ASTRO) highlights that prior authorisations lead to serious adverse outcomes for people with cancer.
A panel of experts on multiple myeloma review patient cases and discuss the treatment of patients with relapsed/refractory disease, highlighting sequencing strategies and clinical trials…
Luveltamab tazevibulin produced responses in patients with platinum-resistant ovarian cancer.
Oncogene – A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancer
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, comments on the recent developments in the treatment of acute myeloid leukemia (AML), sharing…
With the Oncology Brothers, Uma Borate, MD, discusses how the combination of venetoclax with an IDH1 inhibitor and 7+3 chemotherapy leads to higher remission rates…
Tamoxifen reduced the risk of invasive ipsilateral breast recurrence in patients with good-risk ductal carcinoma in situ.
A 17-year-old child with fibrolamellar hepatocellular carcinoma presented for treatment of recurrence in the right hilum and bilateral lungs discovered during routine surveillance imaging; he…
Our findings suggest that NF1 individuals may have a higher risk for developing melanomas and tend to have thicker melanomas and worse survival compared to…
Cancer touches all of us. Our mission – to contribute to the prevention and cure of cancer – depends on your support. There are many…
A breast cancer diagnosis is almost always followed by invasive biopsies, surgery, radiotherapy, chemotherapy and hormone treatments. But could all that be set to change?
